NPC 15437

interacts with th C1 doamin of protein kinase C

Also Known As:

2,6-diamino-N-((1-(oxotridecyl)-2-piperidinyl)methyl)hexanamide; NPC-15437; Hexanamide, 2,6-diamino-N-((1-(1-oxotridecyl)-2-piperidinyl)methyl)-

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

1.	Hypersensitivity (Allergy) 01/01/2015 - "Post-treatment with ZIP, but not Scr-ZIP and NPC-15437, after the resolution of Car-priming selectively relieved hypersensitivity. "
2.	Medulloblastoma 01/01/2007 - "Likewise, NPC 15437 also significantly potentiated the responsiveness of DAOY medulloblastoma cells to TRAIL. "
3.	Hyperalgesia 01/01/2015 - "In contrast, pre-priming NPC-15437 treatment only prevented Car-induced initial transient hyperalgesia. "
4.	Edema (Dropsy) 09/01/1991 - "NPC 15437 inhibited phorbol ester-induced ear edema in mouse (IC50 = 175 micrograms/ear) demonstrating the ability of NPC 15437 to inhibit PKC-mediated activity in intact cells."
5.	Breast Neoplasms (Breast Cancer) 01/01/1996 - "We assessed the effect of the protein kinase C inhibitor 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)hexanami de (NPC 15437) on the action of anthracyclines, epipodophyllotoxins and vinca alkaloids in P-glycoprotein (Pgp)-expressing CH(R)C5 hamster ovary and MCF-7/Adria(R) human breast cancer cells. "

1.	Member 1 Subfamily B ATP Binding Cassette Transporter
2.	Anthracyclines
3.	Vinca Alkaloids
4.	Protein Kinase C
5.	Phorbol Esters